The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
- PMID: 24037308
- DOI: 10.1007/s00253-013-5218-x
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Abstract
The re-emergence of tuberculosis in recent years led the World Health Organization (WHO) to launch the Stop TB Strategy program. Beside repurposing the existing drugs and exploring novel molecular combinations, an essential step to face the burden of tuberculosis will be to develop new drugs by identifying vulnerable bacterial targets. Recent studies have focused on decaprenylphosphoryl-D-ribose oxidase (DprE1) of Mycobacterium tuberculosis, an essential enzyme involved in cell wall metabolism, for which new promising molecules have proved efficacy as antitubercular agents. This review summarizes the state of the art concerning DprE1 in terms of structure, enzymatic activity and inhibitors. This enzyme is emerging as one of the most vulnerable target in M. tuberculosis.
Similar articles
-
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.ACS Chem Biol. 2015 Jul 17;10(7):1631-6. doi: 10.1021/acschembio.5b00237. Epub 2015 Apr 29. ACS Chem Biol. 2015. PMID: 25906160
-
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.ACS Chem Biol. 2015 Mar 20;10(3):705-14. doi: 10.1021/cb5007163. Epub 2014 Dec 9. ACS Chem Biol. 2015. PMID: 25427196
-
Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.Appl Microbiol Biotechnol. 2012 May;94(4):907-16. doi: 10.1007/s00253-012-4013-4. Epub 2012 Apr 18. Appl Microbiol Biotechnol. 2012. Retraction in: Appl Microbiol Biotechnol. 2012 Sep;95(5):1369. doi: 10.1007/s00253-012-4217-7. PMID: 22526781 Retracted. Review.
-
Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6451-6459. doi: 10.1128/AAC.01523-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27527085 Free PMC article.
-
DprE1--from the discovery to the promising tuberculosis drug target.Curr Pharm Des. 2014;20(27):4379-403. doi: 10.2174/138161282027140630122724. Curr Pharm Des. 2014. PMID: 24245764 Review.
Cited by
-
Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds.Pharmaceuticals (Basel). 2017 Jun 1;10(2):51. doi: 10.3390/ph10020051. Pharmaceuticals (Basel). 2017. PMID: 28587160 Free PMC article. Review.
-
Functions of nitroreductases in mycobacterial physiology and drug susceptibility.J Bacteriol. 2025 Feb 20;207(2):e0032624. doi: 10.1128/jb.00326-24. Epub 2025 Jan 8. J Bacteriol. 2025. PMID: 39772630 Free PMC article. Review.
-
Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment.Mol Divers. 2024 Dec;28(6):4221-4239. doi: 10.1007/s11030-024-10812-0. Epub 2024 Mar 6. Mol Divers. 2024. PMID: 38448719
-
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.Nat Commun. 2025 Jan 18;16(1):826. doi: 10.1038/s41467-025-56146-9. Nat Commun. 2025. PMID: 39827265 Free PMC article.
-
Racemases and epimerases operating through a 1,1-proton transfer mechanism: reactivity, mechanism and inhibition.Chem Soc Rev. 2021 May 24;50(10):5952-5984. doi: 10.1039/d0cs00540a. Chem Soc Rev. 2021. PMID: 34027955 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical